CN110559256A - Local imiquimod of skin - Google Patents
Local imiquimod of skin Download PDFInfo
- Publication number
- CN110559256A CN110559256A CN201910884909.0A CN201910884909A CN110559256A CN 110559256 A CN110559256 A CN 110559256A CN 201910884909 A CN201910884909 A CN 201910884909A CN 110559256 A CN110559256 A CN 110559256A
- Authority
- CN
- China
- Prior art keywords
- parts
- imiquimod
- honeysuckle
- chrysanthemum
- tween
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Abstract
the invention discloses imiquimod for local skin, which comprises the following raw materials in parts by weight: 20-30 parts of imiquimod, 12-25 parts of glycerol, 10-20 parts of ethanol, 3-8 parts of boric acid, 3-7 parts of chrysanthemum, 1-6 parts of surfactant, 2-7 parts of gelling agent, 3-5 parts of honeysuckle, 9-15 parts of soybean phospholipid and 24-30 parts of deionized water, and relates to the technical field of medicines. This local use imiquimod of skin, through adding gelatinizer, ethanol and boric acid, make imiquimod become latex-like, can form gelatin on the skin surface after using, make the drug effect can last for a long time and on-stick clothes, through adding honeysuckle and chrysanthemum extract, the disinfection bactericidal effect and the no side effect of imiquimod have further been improved, prepare imiquimod into the solvent when preparing, make imiquimod can fully fuse with other effective substance, make the drug effect can carry out even dispersion to patient's affected part, this imiquimod preparation step is simple and easy simultaneously, and facilitate promotion.
Description
Technical Field
the invention relates to the technical field of medicines, in particular to imiquimod for local skin.
background
Imiquimod, which belongs to imidazole quinoline compounds. Is a small molecule immunomodulator. The mechanism of action for treating external genitalia and perianal warts is not clear. The product has no direct antiviral activity, and does not cause direct and nonspecific cytolytic destruction. However, preclinical studies suggest that it may induce in vivo cytokines including INF- α to produce antiviral activity, and condyloma acuminatum, also known as genital wart or venereal wart, is a sexually transmitted disease caused by human papilloma virus. The incubation period is about 3 months, the short one is 3 weeks, the long one is more than 8 months, the average period is 3 months, and the imiquimod cream can generate immune regulation and indirect antiviral effects and inhibit virus invasion and infection.
the existing imiquimod cream is easy to volatilize when in use, so that the duration time of the drug effect is short, a good treatment effect is not achieved, and when the imiquimod is prepared, the preparation steps are complicated.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides an imiquimod for local skin, and solves the problems that the existing imiquimod has short duration of drug effect, is easy to be erased and has complex preparation steps.
(II) technical scheme
In order to achieve the purpose, the invention is realized by the following technical scheme: the imiquimod for local skin comprises the following raw materials in parts by weight: 20-30 parts of imiquimod, 12-25 parts of glycerol, 10-20 parts of ethanol, 3-8 parts of boric acid, 3-7 parts of chrysanthemum, 1-6 parts of surfactant, 2-7 parts of gelling agent, 3-5 parts of honeysuckle, 9-15 parts of soybean phospholipid and 24-30 parts of deionized water.
Preferably, the raw materials comprise the following components: 20 parts of imiquimod, 12 parts of glycerol, 10 parts of ethanol, 8 parts of boric acid, 7 parts of chrysanthemum, 6 parts of surfactant, 7 parts of gelling agent, 5 parts of honeysuckle, 15 parts of soybean phospholipid and 30 parts of deionized water.
Preferably, the raw materials comprise the following components: 25 parts of imiquimod, 19 parts of glycerol, 15 parts of ethanol, 6 parts of boric acid, 5 parts of chrysanthemum, 3 parts of surfactant, 4 parts of gelling agent, 4 parts of honeysuckle, 13 parts of soybean phospholipid and 26 parts of deionized water.
preferably, the raw materials comprise the following components: 30 parts of imiquimod, 25 parts of glycerol, 20 parts of ethanol, 3 parts of boric acid, 3 parts of chrysanthemum, 1 part of surfactant, 2 parts of gelling agent, 3 parts of honeysuckle, 9 parts of soybean phospholipid and 24 parts of deionized water.
Preferably, the surfactant is one or a mixture of more than two of tween 20, tween 21, tween 40, tween 60, tween 61, tween 65, tween 80, tween 81, tween 85, span 20, span 40, span 60, span 65, span 80, span 83, span 85 and castor oil polyoxyethylene ether, and the gelling agent is a mixture of carbomer and gelatin.
Preferably, the preparation method specifically comprises the following steps:
S1, selecting 20-30 parts of imiquimod as a raw material, 12-25 parts of glycerol, 10-20 parts of ethanol, 3-8 parts of boric acid, 3-7 parts of chrysanthemum, 1-6 parts of surfactant, 2-7 parts of gelling agent, 3-5 parts of honeysuckle, 9-15 parts of soybean phospholipid and 24-30 parts of deionized water, and weighing the raw materials according to the weight ratio;
S2, selecting the ethanol, the boric acid and the deionized water weighed in the S1, adding the ethanol, the boric acid and the deionized water into a mixing stirrer, stirring for 6-9min, controlling the rotation speed of the mixing stirrer to be 200-220r/min and the temperature to be 30-50 ℃ to obtain a solvent, selecting the imiquimod and the glycerol weighed in the S1, fully stirring the glycerol and the imiquimod to obtain wet imiquimod, adding the wet imiquimod into the solvent, stirring for 10-15min, controlling the rotation speed of the mixing stirrer to be 150-180r/min and the temperature to be 40-60 ℃ to obtain the imiquimod solvent;
S3, selecting the honeysuckle and the chrysanthemum weighed in S1, adding the honeysuckle and the chrysanthemum into a heating container, adding water with the proportion twice that of the honeysuckle and the chrysanthemum into the heating container, heating for 30-40min, controlling the water temperature at 80-90 ℃, draining the honeysuckle and the chrysanthemum after heating is finished to obtain a honeysuckle and chrysanthemum solution, and concentrating the solution to obtain a honeysuckle and chrysanthemum extracting solution;
s4, selecting the soybean phospholipid, the gelling agent and the surfactant which are weighed in the S1, adding the imiquimod solvent which is prepared in the S2 and the honeysuckle and chrysanthemum extracting solution which is prepared in the S3 into a mixing stirrer, controlling the rotating speed of the mixing stirrer at 150-180r/min and the temperature at 40-60 ℃, and stirring for 30-40min to obtain the final imiquimod cream.
(III) advantageous effects
The invention provides imiquimod for topical application to the skin. Compared with the prior art, the method has the following beneficial effects: the imiquimod for skin local use comprises the following raw materials in parts by weight: 20-30 parts of imiquimod, 12-25 parts of glycerol, 10-20 parts of ethanol, 3-8 parts of boric acid, 3-7 parts of chrysanthemum, 1-6 parts of surfactant, 2-7 parts of gelling agent, 3-5 parts of honeysuckle, 9-15 parts of soybean phospholipid, 24-30 parts of deionized water, S2, selecting the ethanol, the boric acid and the deionized water weighed in S1, adding the ethanol, the boric acid and the deionized water into a mixing stirrer, stirring for 6-9min, controlling the rotating speed of the mixing stirrer to be 200-220r/min, controlling the temperature to be 30-50 ℃ to obtain a solvent, S3, selecting the honeysuckle and the chrysanthemum weighed in S1, adding the honeysuckle and the chrysanthemum into a heating container, adding water with the proportion being two times that of the honeysuckle and the chrysanthemum into the heating container, S4, selecting the soybean phospholipid, the gelling agent and the surfactant weighed in S1, The imiquimod solvent prepared in the S2 and the honeysuckle and chrysanthemum extracting solution prepared in the S3 are added into a mixing stirrer to obtain the final imiquimod cream, the imiquimod is made into a cream shape by adding the gelling agent, the ethanol and the boric acid, the gelatin can be formed on the surface of skin after use and is waterproof, the drug effect can be lasting for a long time and does not stick to clothes, the sterilizing effect of the imiquimod is further improved and no side effect is caused by adding the honeysuckle and chrysanthemum extracting solution, the imiquimod is prepared into the solvent during preparation, the imiquimod can be fully fused with other effective substances, the drug effect can be uniformly dispersed on affected parts of patients, and the imiquimod cream has a good effect on treating condyloma acuminata.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The embodiment of the invention provides three technical schemes: a method for preparing imiquimod for local skin application specifically comprises the following embodiments:
Example 1
s1, selecting 20 parts of imiquimod, 12 parts of glycerol, 10 parts of ethanol, 8 parts of boric acid, 7 parts of chrysanthemum, 6 parts of surfactant, 7 parts of gelling agent, 5 parts of honeysuckle, 15 parts of soybean phospholipid and 30 parts of deionized water, respectively weighing the raw materials according to the weight ratio, wherein the surfactant is one or a mixture of more than two of Tween 20, Tween 21, Tween 40, Tween 60, Tween 61, Tween 65, Tween 80, Tween 81, Tween 85, span 20, span 40, span 60, span 65, span 80, span 83, span 85 and castor oil polyoxyethylene ether, and the gelling agent is a mixture of carbomer and gelatin;
S2, selecting the ethanol, the boric acid and the deionized water weighed in the S1, adding the ethanol, the boric acid and the deionized water into a mixing stirrer, stirring for 6-9min, controlling the rotation speed of the mixing stirrer to be 200r/min and the temperature to be 30 ℃ to obtain a solvent, selecting the imiquimod and the glycerol weighed in the S1, fully stirring the glycerol and the imiquimod to obtain wet imiquimod, adding the wet imiquimod into the solvent, stirring for 10min, controlling the rotation speed of the mixing stirrer to be 150r/min and the temperature to be 40 ℃ to obtain the imiquimod solvent;
S3, selecting the honeysuckle and the chrysanthemum weighed in S1, adding the honeysuckle and the chrysanthemum into a heating container, adding water with the proportion twice that of the honeysuckle and the chrysanthemum into the heating container, heating for 30min, controlling the water temperature at 80 ℃, draining the honeysuckle and the chrysanthemum after heating to obtain a honeysuckle and chrysanthemum solution, and concentrating the solution to obtain a honeysuckle and chrysanthemum extracting solution;
s4, selecting the soybean phospholipid, the gelling agent and the surfactant which are weighed in the S1, adding the imiquimod solvent which is prepared in the S2 and the honeysuckle and chrysanthemum extracting solution which is prepared in the S3 into a mixing stirrer, controlling the rotating speed of the mixing stirrer at 150r/min and the temperature at 40 ℃, and stirring for 30min to obtain the final imiquimod cream.
example 2
s1, selecting 25 parts of imiquimod, 19 parts of glycerol, 15 parts of ethanol, 6 parts of boric acid, 5 parts of chrysanthemum, 3 parts of surfactant, 4 parts of gelling agent, 4 parts of honeysuckle, 13 parts of soybean phospholipid and 26 parts of deionized water, respectively weighing the raw materials according to the weight ratio, wherein the surfactant is one or a mixture of more than two of Tween 20, Tween 21, Tween 40, Tween 60, Tween 61, Tween 65, Tween 80, Tween 81, Tween 85, span 20, span 40, span 60, span 65, span 80, span 83, span 85 and castor oil polyoxyethylene ether, and the gelling agent is a mixture of carbomer and gelatin;
S2, selecting the ethanol, the boric acid and the deionized water weighed in the S1, adding the ethanol, the boric acid and the deionized water into a mixing stirrer, stirring for 7min, controlling the rotation speed of the mixing stirrer to be 210r/min and the temperature to be 40 ℃ to obtain a solvent, selecting the imiquimod and the glycerol weighed in the S1, fully stirring the glycerol and the imiquimod to obtain wet imiquimod, adding the wet imiquimod into the solvent, stirring for 12min, controlling the rotation speed of the mixing stirrer to be 160r/min and the temperature to be 50 ℃ to obtain the imiquimod solvent;
S3, selecting the honeysuckle and the chrysanthemum weighed in S1, adding the honeysuckle and the chrysanthemum into a heating container, adding water with the proportion twice that of the honeysuckle and the chrysanthemum into the heating container, heating for 35min, controlling the water temperature at 85 ℃, draining the honeysuckle and the chrysanthemum after heating to obtain a honeysuckle and chrysanthemum solution, and concentrating the solution to obtain a honeysuckle and chrysanthemum extracting solution;
S4, selecting the bean lecithin, the gelling agent and the surfactant which are weighed in the S1, adding the imiquimod solvent which is prepared in the S2 and the honeysuckle and chrysanthemum extracting solution which is prepared in the S3 into a mixing stirrer, controlling the rotating speed of the mixing stirrer at 165r/min and the temperature at 50 ℃, and stirring for 35min to obtain the final imiquimod cream.
Example 3
s1, selecting 30 parts of imiquimod as a raw material, 25 parts of glycerol, 20 parts of ethanol, 3 parts of boric acid, 3 parts of chrysanthemum, 1 part of surfactant, 2 parts of gelling agent, 3 parts of honeysuckle, 9 parts of soybean phospholipid and 24 parts of deionized water, respectively weighing the raw materials according to the weight ratio, wherein the surfactant is one or a mixture of more than two of Tween 20, Tween 21, Tween 40, Tween 60, Tween 61, Tween 65, Tween 80, Tween 81, Tween 85, span 20, span 40, span 60, span 65, span 80, span 83, span 85 and castor oil polyoxyethylene ether, and the gelling agent is a mixture of carbomer and gelatin;
S2, selecting the ethanol, the boric acid and the deionized water weighed in the S1, adding the ethanol, the boric acid and the deionized water into a mixing stirrer, stirring for 9min, controlling the rotating speed of the mixing stirrer to be 220r/min and the temperature to be 50 ℃ to obtain a solvent, selecting the imiquimod and the glycerol weighed in the S1, fully stirring the glycerol and the imiquimod to obtain wet imiquimod, adding the wet imiquimod into the solvent, stirring for 15min, controlling the rotating speed of the mixing stirrer to be 180r/min and the temperature to be 60 ℃ to obtain the imiquimod solvent;
S3, selecting the honeysuckle and the chrysanthemum weighed in S1, adding the honeysuckle and the chrysanthemum into a heating container, adding water with the proportion twice that of the honeysuckle and the chrysanthemum into the heating container, heating for 40min, controlling the water temperature at 90 ℃, draining the honeysuckle and the chrysanthemum after heating to obtain a honeysuckle and chrysanthemum solution, and concentrating the solution to obtain a honeysuckle and chrysanthemum extracting solution;
s4, selecting the soybean phospholipid, the gelling agent and the surfactant which are weighed in the S1, adding the imiquimod solvent which is prepared in the S2 and the honeysuckle and chrysanthemum extracting solution which is prepared in the S3 into a mixing stirrer, controlling the rotating speed of the mixing stirrer at 180r/min and the temperature at 60 ℃, and stirring for 40min to obtain the final imiquimod cream.
Effects of the embodiment
mr. Wang, age 35, had condyloma acuminatum in the anal region, and after continuously using the imiquimod prepared in examples 1-3 for 10-15 days, had significant resolution of condyloma acuminatum without any side effects, and clinical observation shows that after the imiquimod is applied, daily life is normally performed, and the efficacy of imiquimod can last for 24 hours.
the female is 40 years old, the vagina is suffered from condyloma acuminatum, after 8-10 days of continuous use of the imiquimod prepared in examples 1-3, the condyloma acuminatum in the vagina is obviously dissipated, no diffusion phenomenon exists, no side effect exists, through clinical observation, after the imiquimod is smeared, urination is normally carried out, the imiquimod can still be adsorbed on the affected part, and the drug effect is normal.
it is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
Claims (6)
1. Topical imiquimod for skin, characterized by: the raw materials comprise the following components in parts by weight: 20-30 parts of imiquimod, 12-25 parts of glycerol, 10-20 parts of ethanol, 3-8 parts of boric acid, 3-7 parts of chrysanthemum, 1-6 parts of surfactant, 2-7 parts of gelling agent, 3-5 parts of honeysuckle, 9-15 parts of soybean phospholipid and 24-30 parts of deionized water.
2. A topical imiquimod for skin according to claim 1, wherein: the raw materials comprise the following components: 20 parts of imiquimod, 12 parts of glycerol, 10 parts of ethanol, 8 parts of boric acid, 7 parts of chrysanthemum, 6 parts of surfactant, 7 parts of gelling agent, 5 parts of honeysuckle, 15 parts of soybean phospholipid and 30 parts of deionized water.
3. A topical imiquimod for skin according to claim 1, wherein: the raw materials comprise the following components: 25 parts of imiquimod, 19 parts of glycerol, 15 parts of ethanol, 6 parts of boric acid, 5 parts of chrysanthemum, 3 parts of surfactant, 4 parts of gelling agent, 4 parts of honeysuckle, 13 parts of soybean phospholipid and 26 parts of deionized water.
4. A topical imiquimod for skin according to claim 1, wherein: the raw materials comprise the following components: 30 parts of imiquimod, 25 parts of glycerol, 20 parts of ethanol, 3 parts of boric acid, 3 parts of chrysanthemum, 1 part of surfactant, 2 parts of gelling agent, 3 parts of honeysuckle, 9 parts of soybean phospholipid and 24 parts of deionized water.
5. A topical imiquimod according to any one of claims 1 to 4, wherein: the surfactant is one or a mixture of more than two of Tween 20, Tween 21, Tween 40, Tween 60, Tween 61, Tween 65, Tween 80, Tween 81, Tween 85, span 20, span 40, span 60, span 65, span 80, span 83, span 85 and castor oil polyoxyethylene ether, and the gelling agent is a mixture of carbomer and gelatin.
6. a topical imiquimod according to any one of claims 1 to 4, wherein: the preparation method specifically comprises the following steps:
S1, selecting 20-30 parts of imiquimod as a raw material, 12-25 parts of glycerol, 10-20 parts of ethanol, 3-8 parts of boric acid, 3-7 parts of chrysanthemum, 1-6 parts of surfactant, 2-7 parts of gelling agent, 3-5 parts of honeysuckle, 9-15 parts of soybean phospholipid and 24-30 parts of deionized water, and weighing the raw materials according to the weight ratio;
S2, selecting the ethanol, the boric acid and the deionized water weighed in the S1, adding the ethanol, the boric acid and the deionized water into a mixing stirrer, stirring for 6-9min, controlling the rotation speed of the mixing stirrer to be 200-220r/min and the temperature to be 30-50 ℃ to obtain a solvent, selecting the imiquimod and the glycerol weighed in the S1, fully stirring the glycerol and the imiquimod to obtain wet imiquimod, adding the wet imiquimod into the solvent, stirring for 10-15min, controlling the rotation speed of the mixing stirrer to be 150-180r/min and the temperature to be 40-60 ℃ to obtain the imiquimod solvent;
S3, selecting the honeysuckle and the chrysanthemum weighed in S1, adding the honeysuckle and the chrysanthemum into a heating container, adding water with the proportion twice that of the honeysuckle and the chrysanthemum into the heating container, heating for 30-40min, controlling the water temperature at 80-90 ℃, draining the honeysuckle and the chrysanthemum after heating is finished to obtain a honeysuckle and chrysanthemum solution, and concentrating the solution to obtain a honeysuckle and chrysanthemum extracting solution;
S4, selecting the soybean phospholipid, the gelling agent and the surfactant which are weighed in the S1, adding the imiquimod solvent which is prepared in the S2 and the honeysuckle and chrysanthemum extracting solution which is prepared in the S3 into a mixing stirrer, controlling the rotating speed of the mixing stirrer at 150-180r/min and the temperature at 40-60 ℃, and stirring for 30-40min to obtain the final imiquimod cream.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910884909.0A CN110559256A (en) | 2019-09-19 | 2019-09-19 | Local imiquimod of skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910884909.0A CN110559256A (en) | 2019-09-19 | 2019-09-19 | Local imiquimod of skin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110559256A true CN110559256A (en) | 2019-12-13 |
Family
ID=68781365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910884909.0A Pending CN110559256A (en) | 2019-09-19 | 2019-09-19 | Local imiquimod of skin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110559256A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1864664A (en) * | 2006-06-13 | 2006-11-22 | 湖北科益药业股份有限公司 | Lmiquimod cream and preparation method thereof |
| US20070123558A1 (en) * | 2004-12-17 | 2007-05-31 | Statham Alexis S | Immune response modifier formulations containing oleic acid and methods |
| CN101756886A (en) * | 2010-02-09 | 2010-06-30 | 华中师范大学 | Imiquimod micro emulsion gels for local skin and preparation method thereof |
| CN105056034A (en) * | 2015-09-03 | 2015-11-18 | 南京正宽医药科技有限公司 | Care solution for treating condyloma acuminatum of vulva |
-
2019
- 2019-09-19 CN CN201910884909.0A patent/CN110559256A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070123558A1 (en) * | 2004-12-17 | 2007-05-31 | Statham Alexis S | Immune response modifier formulations containing oleic acid and methods |
| CN1864664A (en) * | 2006-06-13 | 2006-11-22 | 湖北科益药业股份有限公司 | Lmiquimod cream and preparation method thereof |
| CN101756886A (en) * | 2010-02-09 | 2010-06-30 | 华中师范大学 | Imiquimod micro emulsion gels for local skin and preparation method thereof |
| CN105056034A (en) * | 2015-09-03 | 2015-11-18 | 南京正宽医药科技有限公司 | Care solution for treating condyloma acuminatum of vulva |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105816908B (en) | Waterproof liquid wound protection film and preparation method thereof | |
| CA1069046A (en) | Tar gel formulation | |
| DE69732402T2 (en) | Composition for the treatment of condyloma acuminata | |
| CN108524866A (en) | A kind of Traditional Chinese medicine bacteriostatic gelling agent and preparation method thereof | |
| CN105362351A (en) | Medicine composition for treating cutaneous pruritus disease and application thereof | |
| JP4361867B2 (en) | Skin external preparation composition for prevention and treatment of acne | |
| CN114668000B (en) | Preparation method of slow-release safe inorganic antibacterial agent for mosquito repellent liquid and mosquito repellent liquid | |
| EP2528609B1 (en) | Propolis and process for the treatment thereof and end products formed therefrom | |
| JPS6351126B2 (en) | ||
| CN107137576A (en) | A kind of pharmaceutical preparation for preventing and treating human papilloma virus infection and preparation method thereof | |
| CN110559256A (en) | Local imiquimod of skin | |
| CA2283314C (en) | Ointment for the treatment of burns and of other skin diseases | |
| CN104784297A (en) | Skin allergy prevention composition | |
| CN100525797C (en) | Vagina external-use medicine composition and its preparing method and use | |
| KR20060036168A (en) | Vagina cleansing composite having punica grantum extract and fabricating method therefor | |
| KR20060112061A (en) | COMPOSITIION FOR INHIBITING 5alpha;-REDUCTASE ACTIVITY AND COSMETIC COMPOSITION FOR INHIBITING SECRETION OF SEBUM CONTAINING EXTRACT OF ULMUS DAVIDIANA AS ACTIVE INGREDIENT | |
| CN110123703A (en) | One kind resisting antibacterial nursing cleaning curing agent and preparation method for gynaecology's secret | |
| CN112220961B (en) | Mattress-proof deodorization chip, puerpera pad and preparation method of mattress-proof deodorization chip | |
| CN107789611A (en) | A kind of collagen peptide lubricating fluid and preparation method thereof | |
| CN106389974A (en) | Method for preparing traditional Chinese medicine ointment for preventing and treating dog fungus skin diseases | |
| CN111407770A (en) | Composition for treating skin diseases and application thereof | |
| CN110368453A (en) | A kind of anti-acne thermo-sensitive gel and preparation method thereof | |
| CN110179871A (en) | A kind of external medicine composition and preparation method thereof for treating eczema | |
| CN107362310A (en) | It is a kind of to be used to repair Baicao Fuyanqing preparation of vagina environment and preparation method thereof | |
| CN112807339A (en) | Emulsifiable paste for treating infantile eczema and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191213 |
|
| RJ01 | Rejection of invention patent application after publication |